Re-stratification of Patients with High-Risk Prostate Cancer According to the NCCN Guidelines among Patients Who Underwent Radical Prostatectomy: An Analysis Based on the K-CaP Registry by 援ш탳泥� et al.
│ http://www.e-crt.org │88 Copyright ⓒ 2018 by  the Korean Cancer Association
This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Cancer Res Treat. 2018;50(1):88-94
pISSN 1598-2998, eISSN 2005-9256
https://doi.org/10.4143/crt.2016.494
Open Access
Re-stratification of Patients with High-Risk Prostate Cancer According
to the NCCN Guidelines among Patients Who Underwent Radical
Prostatectomy: An Analysis Based on the K-CaP Registry
Original Article
Purpose
The present study aimed to re-stratify patients with high-risk prostate cancer according to
the National Comprehensive Cancer Network guidelines among patients who underwent
radical prostatectomy (RP).
Materials and Methods
This study used the Korean Prostate Cancer Database registry and identified 1,060 patients
with high-risk prostate cancer who underwent RP between May 2001 and April 2013. All 
patients were categorized into risk groups, and subgroups were identified according to the
type and number of high-risk factors. 
Results
Of the 1,060 high-risk patients, 599 (56.5%), 408 (38.5%), and 53 (5.0%) had 1, 2, and 3
risk factors, respectively. In multivariate analysis, the Gleason score, percentage of positive
biopsy cores, and number of risk factors present were identified as independent predictors
of biochemical recurrence. There were significant differences in the 5-year postoperative
biochemical failure-free survival (BCFFS) rate among the different high-risk factor subgroups
(log-rank p < 0.001). There were no significant differences in the BCFFS rate between the
subgroup of high-risk patients with a prostate-specific antigen level > 20 ng/mL alone and
the intermediate-risk group with all factors (log-rank p=0.919 and p=0.781, respectively).
Additionally, no significant difference was noted in the BCFFS rate between high-risk patients
having all factors and those in the very-high-risk group (p=0.566). 
Conclusion
We successfully re-stratified patients with high-risk prostate cancer and identified the com-
binations of high-risk criteria that will help in the selection of patients for RP. 
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Introduction
Prostate cancer (PCa) has been reported to be the most
common malignancy among elderly men in Western coun-
tries [1,2]. In Asia, the incidence and detection of PCa have
recently increased. Several factors, including environmental
factors, changes in Western dietary habits, medical advances
in laboratory diagnosis, and campaigns for prostate-specific
antigen (PSA) screening, are believed to be associated with
the increased incidence of PCa [3]. A previous study has 
reported that many patients present with locally advanced
disease [4]. 
Several treatment options, including radical prostatectomy
(RP), radiation therapy (RT), androgen deprivation therapy
(ADT), and multidisciplinary therapy, have been recom-
mended for patients with high-risk PCa. Most previous stud-
ies that assessed the efficacy of RP, RT, or multidisciplinary
therapy for patients with high-risk PCa have demonstrated
extremely heterogeneous outcomes according to treatment
modality [1,5-8], but there is no data from a multicenter data-
base of high-risk patients with RP. Among patients at high
risk of failure following standard therapy, RP allows for
treatment individualization by carefully selecting patients
who might benefit from treatment. Therefore, it is necessary
to revisit the classification system and attempt to better strat-
ify patients within this heterogeneous high-risk PCa group.
There is no consensus on the definition of high-risk PCa
[1,5,9,10]. In practice, patients with PCa are treated based on
the recommendations of the National Comprehensive Can-
cer Network (NCCN) guidelines. Patients with intermediate
and high-risk PCa with multiple adverse factors may be
shifted to the next highest risk subgroup [9]. Recently, the
NCCN guidelines recommended that patients with high-risk
PCa (T3a or Gleason score 8-10 or PSA > 20 ng/mL) with pri-
mary Gleason pattern 5 or more than 4 cores with Gleason
score 8 to 10 should be classified as very high-risk patients,
with RP recommended for select patients. Using this classi-
fication system, urologists can predict oncological outcomes,
including biochemical recurrence (BCR) after definitive ther-
apy, and select appropriate candidates for RP from among
patients with high-risk PCa. The present study aimed to fur-
ther classify a large cohort of patients with high-risk PCa
who underwent RP according to the NCCN guidelines.
Materials and Methods
The study used the Korean Prostate Cancer Database 
(K-CaP) registry. The K-CaP registry was established in 2014
as the first registry for comprehensive data collection with
regard to Korean patients with PCa who underwent RP [11].
Patients with PCa who underwent RP at five Korean tertiary
referral hospitals (Asan Medical Center, Samsung Medical
Center, Seoul National University Bundang Hospital, Seoul
St. Mary’s Hospital, and Yonsei University Severance Hos-
pital) between 2001 and 2012 were eligible for inclusion in
the K-CaP registry. The K-CaP registry included a total of
3,206 patients. Patients with a PSA level > 20 ng/mL, a Glea-
son score of 8-10 on prostate biopsy, or a clinical stage of T3a
using prostate magnetic resonance imaging (MRI) were con-
sidered to have high-risk PCa according to the 2016 NCCN
guidelines [9]. After excluding patients who received neoad-
juvant ADT and those without complete clinicopathological
data, 1,060 patients with high-risk PCa were finally enrolled
in this study. 
The MRI data of the enrolled patients were interpreted by
radiologists in the urology department at each participating
hospital. The final pathology was determined using RP spec-
imens and was reported by the pathologists in the urology
department of each institution. The clinicopathological stage
was assigned according to the 2002 TNM staging system, and
prostate biopsy cores were obtained with transrectal ultra-
sound guidance using a > 10-core biopsy protocol. An 
adverse pathologic feature was defined as the occurrence of
pathologic stage " T3b cancer. The percent of positive biopsy
cores as a continuous variable was defined as the positive
core count divided by the total core count. 
Clinicopathological data, such as age at surgery, previous
medical history, PSA level at diagnosis, prostate size on pre-
operative imaging studies, prostate biopsy-related variables,
operative method, and pathological outcomes (pathological
stage, Gleason score, and surgical margin status), were 
extracted from the K-CaP registry. Biochemical failure (BCF)
was defined as (1) a confirmed rise in the PSA level above
the threshold of 0.2 ng/mL, (2) a failure of PSA to fall to 
undetectable levels, or (3) the use of additional therapy 
including RT or ADT.
This study was performed after obtaining approval from
the Institutional Review Board (2016-0493-001). The patient
and tumor characteristics were compared using Pearson’s
chi-square test and Student’s t test. Cox univariate and mul-
tivariate analyses were performed to assess the clinical vari-
ables predictive of BCF in all patients with high-risk PCa. The
postoperative BCF-free survival (BCFFS) rate of each patient
group was calculated and compared using Kaplan-Meier
analysis with a log-rank test. All statistical analyses were per-
formed using SPSS ver. 21 (IBM Corp., Armonk, NY). A 
p-value of < 0.05 was considered to indicate a statistically sig-
nificant difference.
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Results
Table 1 presents the baseline characteristics of the interme-
diate-risk, high-risk, and very-high-risk PCa groups based on
the NCCN guidelines. Of the 1,060 patients with high-risk PCa
included in this study, open RP, laparoscopic RP, and robot-
assisted laparoscopic prostatectomy were performed in 359
(33.9%), 17 (1.6%), and 684 (64.5%) patients, respectively. The
median duration of postoperative follow-up was 48.8 months
(interquartile range, 32.0 to 60.0 months). The number of 
patients with 1, 2, and 3 risk factors was 599 (56.5%), 408
(38.5%), and 53 (5.0%), respectively. According to the risk clas-
sification, the mean PSA level was 15.68 ng/mL for one risk
factor, 23.92 ng/mL for two risk factors, and 38.96 ng/mL for
three risk factors, respectively (p < 0.001). The proportions of
the clinical stage were different between the three groups 
(! T2a, 72.4%, 45.9%, and 0%; cT2b-cT2c, 14.5%, 33.4% and 0%;
cT3a, 13.0%, 20.6%, and 100.0% for 1, 2, and 3 risk factors, 
respectively [p < 0.001]). There were significant differences in
the rates of adverse pathological features among the different
high-risk factor subgroups (1 vs. 2 vs. 3, 3.5% vs. 19.1% vs.
20.8%; p=0.001). The proportion of perineural invasion 
increased with the number of risk factors (1 vs. 2 vs. 3, 50.6%
vs. 63.0% vs. 83.0%; p=0.001). 
In the multivariate Cox proportional hazards models, 
including age, body mass index, PSA level (> 20 ng/mL vs. 20
ng/mL), PSA density, stage (T3a vs. ! T2c), Gleason score 
(" 8 vs. ! 7), and percent of positive biopsy cores, we found
that PSA level, PSA density, stage, Gleason score, and percent
of positive biopsy cores were independent predictors of BCF
in the high-risk PCa group. Of high-risk factors, the strongest
predictor of progression and mortality was the Gleason score
(Table 2). We evaluated the comparative survival of and num-
ber of high-risk factors (" 2 vs. 1) after adjustment for covari-
ates considered potential predictors by the Cox proportional
hazards analysis for BCF (hazard ratio, 1.36; 1.016 to 1.826;
p=0.039).
We found significant differences in the 5-year postoperative
BCFFS rate among the different high-risk factor subgroups 
(1 vs. 2 vs. 3, 43.0% vs. 21.0% vs. 0%; log-rank p < 0.001). How-
ever, there was no significant difference in the BCFFS rate 
between the high-risk group with one factor and the interme-
diate-risk group with all factors (log-rank p=0.919) (Fig. 1). On
Univariate analysis Multivariate analysisVariable
Hazard ratio (95% CI) p-value Hazard ratio (95% CI) p-value
Age (yr)a) 1.01 (0.996-1.027) 0.148 - -
BMI (< 25 kg/m2 vs. " 25 kg/m2) 1.04 (0.890-1.207) 0.641 - -
Prostate volume (cm3)a) 1.00 (0.991-1.001) 0.081 - -
PSAD (ng/mL/cm3)a) 1.59 (1.440-1.764) < 0.001 1.33 (1.162-1.515) < 0.001
PSA (> 20 ng/mL vs. 20 ng/mL) - < 0.001 1.66 (1.355-2.030) < 0.001
Stage (T3a vs. ! T2c) 2.86 (2.325-3.524) < 0.001 1.51 (1.112-2.036) < 0.001
Gleason score (" 8 vs. ! 7) 2.83 (2.422-3.298) < 0.001 2.00 (1.623-2.461) < 0.001
Positive biopsy core (%)a) 1.14 (1.111-1.178) < 0.001 1.93 (1.333-2.778) < 0.001
Table 2. Univariate and multivariate analyses for the identification of the significant predictors of postoperative biochemical
failure in the high-risk group
CI, confidence interval; BMI, body mass index; PSAD, prostate-specific antigen density; PSA, prostate-specific antigen. a)Con-
tinuous variable.
Fig. 1. Biochemical recurrence (BCR) in the very-low-risk,
low-risk, intermediate-risk, high-risk, very-high-risk, and
metastatic-risk groups.
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further analyzing the high-risk group with one factor, we
found that the BCFFS rate was similar between the subgroup
of patients with a PSA level > 20 ng/mL alone and the inter-
mediate-risk group with all factors (log-rank p=0.781, p=0.001,
and p < 0.001 for the factors, respectively). On comparing bio-
chemical outcomes between patients having all high-risk fac-
tors and those in the very-high-risk group, no significant
difference was found in the BCFFS rate (log-rank p=0.566).
Discussion
In the present study, we observed heterogeneous patho-
logical and biochemical outcomes among patients who 
underwent RP for high-risk PCa according to the NCCN
guidelines [9]. We found that BCFFS was related to the num-
ber of high-risk factors. This study will help in the selection
of patients for RP using combinations of present high-risk
criteria. Overall, our findings support the accurate character-
ization of patients with high-risk PCa according to the new
NCCN risk stratification.
The main considerations when deciding on PCa treatment
are the risk factors, including the PSA level, TNM clinical
stage, Gleason score, age, and comorbidities. At present,
urologists face the dilemma of deciding which treatment is
best adapted for patients with high-risk PCa: RP, RT, or mul-
tidisciplinary therapy. Several studies have assessed risk
stratification using different approaches, such as the Kattan
nomogram and Cancer of the Prostate Risk Assessment
[12,13]. With regard to digital rectal examination and com-
puted tomography, clinical staging can be imprecise for the
evaluation of extraprostatic disease. MRI is believed to 
improve the accuracy of clinical staging. In our study, all 
patients were stratified into new risk groups according to the
NCCN guidelines using prostate MRI for precise clinical
staging. 
Clinically useful criteria for defining high-risk PCa should
reliably distinguish patients who might be optimal candi-
dates for RP. Prospective randomized trials have been per-
formed to provide insight into treatment strategies; however,
the optimal strategy has not been definitively identified 
[14-16]. The NCCN guidelines suggest criteria that divide 
patients with high-risk PCa into various groups according to
distinct clinical outcomes. The very-high-risk group is 
defined by the following criteria at diagnosis: a primary
Gleason pattern of 5 or > 4 cores with a Gleason score of 
8-10 and clinical stage T3b-4. Therefore, there have been no
previous studies with a proper target patient group.
High-risk patients are generally at an elevated risk for
early BCR, metastatic progression, and death from PCa
[10,17,18]. Therefore, a consensus on the definition of high-
risk PCa is considered a priority [3]. Yossepowitch et al. [17]
reported that the 5-year biochemical recurrence-free survival
rate ranged from 49% to 80% according to eight different def-
initions of high-risk PCa. In this study, a PSA level > 20
ng/mL, stage cT3, and a positive biopsy core with a Gleason
score of 8-10 individually or in combination were considered
factors associated with high-risk disease. Joniau et al. [19]
compared PCa-specific survival using seven different defi-
nitions of high-risk PCa to classify 1,632 patients treated with
RP. The authors suggested stratification of patients with
high-risk PCa into the following three subgroups: good prog-
nosis subgroup (1 high-risk factor); intermediate prognosis
subgroup (PSA level > 20 ng/ mL and stage cT3-4); and poor
prognosis subgroup (Gleason score 8-10 in combination with
at least 1 other high-risk factor). Because of the lack of a def-
inition of high-risk PCa, studies have subclassified high-risk
PCa into different prognostic categories [20,21].
An elevated PSA level (> 20 ng/mL) alone is not enough
to define a high-risk patient. Spahn et al. [22] reported that
the strongest predictor of prostatectomy was the Gleason
score in patients with PSA > 20 ng/mL, and the risk levels
affected disease progression and PCa-specific mortality. We
found that the BCFFS rate was not different between patients
having 1 high-risk factor (PSA level > 20 ng/mL) and pati-
ents in the intermediate-risk group having all factors. With
regard to the PSA level, there can be fluctuations that result
from several factors, including benign prostatic hyperplasia
and other nonmalignant conditions. Considering that many
individuals present with PSA >20 ng/mL as their only high-
risk factor, they may present with favorable pathologic char-
acteristics and could be appropriate candidates for surgery.
As expected, pathologic features and progression were sig-
nificantly different among the three risk categories. In 
patients with one high-risk factor, heterogeneous pathologi-
cal and biochemical outcomes were found. Patients whose
only high-risk factor was an elevated PSA level (> 20 ng/mL)
had a similar prognosis to the intermediate-risk group of 
patients with all factors. The BCFFS rate was not different 
between patients with three high-risk factors and patients in
the very-high-risk group. Our results are consistent with the
recommendation of the NCCN guidelines that the interme-
diate-risk group and patients with high-risk PCa with mul-
tiple adverse factors may be shifted to the next risk group.
For patients with high-risk PCa whose only risk factor is 
elevated PSA level (> 20 ng/mL), we can recommend RP as
the initial therapy in accordance with the intermediate-risk
group, and the high-risk groups with all risk factors should
be considered for multidisciplinary therapy instead of RP. In
conclusion, the clinician could schedule patients already
treated with RP and pelvic lymph node dissection for appro-
priate postoperative management. K-CaP is currently design-
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ing future studies to evaluate whether early postoperative
treatments should consequently be reserved for cases of BCF.
Our study has important strengths. To our knowledge,
this is the first study to provide consistent predictions of 
appropriate oncological endpoints in patients presenting
with high-risk PCa, based on the number and precise com-
bination of risk factors. Few previous studies have described
the outcomes of surgery in patients with high-risk PCa, and
most of these studies have presented a small series or a sin-
gle-center experience. Specifically, after extracting unfavor-
able factors, including a primary Gleason pattern of 5 or > 4
cores with a Gleason score of 8-10, from the high-risk factors
to identify a group of men within the current NCCN high-
risk category who are at greatest risk of metastasis or cancer-
related death despite conventional treatment [23]. our study
indicated which patients may require surgery and which 
patients may not require surgery. Most previous studies
aimed to validate the subset of the high-risk group according
to the oncological outcomes within each risk group [20,24,
25]. The present study identified the oncological outcomes
of each subgroup based on the number of risk factors after
comparison with those in the other risk groups in patients
with high-risk PCa. Furthermore, there were three sub-
groups according to the number of high-risk factors, and the
outcomes, including BCFFS, were compared to those for the
next lowest and highest groups.
Although this study had several strengths, there were
some limitations. Several factors could account for the het-
erogeneity in the results, including the presence of multiple
physicians and the variability of intraoperative management.
Additionally, there was heterogeneity of the treated patients.
Multiple factors influenced the clinical decision-making, 
including age, performance status, and preoperative clinico-
pathological results. In particular, the data on comorbidity
that may have affected treatment policies were not perfect.
In addition, because of factors such as comorbidities, the
prognosis of patients who received other treatments was not
known. In our retrospective cohort, all MRI and pathological
results were not centrally investigated but were assessed by
radiologists and pathologists in the urology department at
each institution. Another limitation is the relatively short fol-
low-up period for patients treated with RP, which did not
allow analysis of metastasis-free survival or cancer-specific
survival. For further survival evaluation, the follow-up 
period should be longer, and more multicenter trials are
needed to clarify whether the oncological outcomes are sim-
ilar between a high-risk group with a PSA level > 20 ng/mL
and an intermediate-risk group with all risk factors. More-
over, it may not be possible to extend our finding of a similar
BCFFS rate between patients having all high-risk factors and
patients in the very-high-risk group to high-risk patients 
undergoing radiotherapy or systemic therapy.
In the present study, we successfully re-stratified patients
with high-risk PCa and noted that the use of combinations
of present high-risk criteria will help in the selection of 
patients for RP. Additionally, we noted heterogeneity in bio-
chemical outcomes among patients with high-risk PCa who
underwent RP. The postoperative BCFFS rate appears to be
similar between patients having 1 high-risk factor (PSA > 20
ng/mL) and patients in the intermediate-risk group and 
between patients having three high-risk factors and patients
in the very-high-risk group.
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